| Oleg N Militsakh, MD | |
|
8303 Dodge St, Suite # 304, Omaha, NE 68114-4108 | |
| (402) 354-5048 | |
| (402) 354-2585 |
| Full Name | Oleg N Militsakh |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 23 Years |
| Location | 8303 Dodge St, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306879291 | NPI | - | NPPES |
| 10025044400 | Medicaid | NE | |
| 1306879291 | Medicaid | MO | |
| 1306879291 | Medicaid | IA |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Methodist Hospital | Omaha, NE | Hospital |
| Methodist Fremont Health | Fremont, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nebraska Methodist Hospital | 6901707447 | 118 |
| Nebraska Methodist Hospital | 6901707447 | 118 |
News Archive
A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state in which they are unable to proliferate.
ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it had received a letter dated September 16, 2009, indicating the Company had become non-compliant with the Nasdaq Capital Markets' minimum bid pricing requirement under rule 5550(a)(2) as the Company's closing bid price for the past 30 days had failed to meet the minimum bid of $1.00 per share.
Even minute amounts of lead may take a toll on pregnant women, according to a study published by Lynn Goldman, M.D., M.S., M.P.H., Dean of George Washington University's School of Public Health and Health Services in D.C., and colleagues, in the journal Environmental Health Perspectives.
MAP Pharmaceuticals, Inc. today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.
› Verified 3 days ago
| Entity Name | Physicians Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821049156 PECOS PAC ID: 4880506062 Enrollment ID: O20031105000345 |
News Archive
A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state in which they are unable to proliferate.
ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it had received a letter dated September 16, 2009, indicating the Company had become non-compliant with the Nasdaq Capital Markets' minimum bid pricing requirement under rule 5550(a)(2) as the Company's closing bid price for the past 30 days had failed to meet the minimum bid of $1.00 per share.
Even minute amounts of lead may take a toll on pregnant women, according to a study published by Lynn Goldman, M.D., M.S., M.P.H., Dean of George Washington University's School of Public Health and Health Services in D.C., and colleagues, in the journal Environmental Health Perspectives.
MAP Pharmaceuticals, Inc. today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.
› Verified 3 days ago
| Entity Name | Nebraska Methodist Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689628372 PECOS PAC ID: 6901707447 Enrollment ID: O20040116000781 |
News Archive
A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state in which they are unable to proliferate.
ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it had received a letter dated September 16, 2009, indicating the Company had become non-compliant with the Nasdaq Capital Markets' minimum bid pricing requirement under rule 5550(a)(2) as the Company's closing bid price for the past 30 days had failed to meet the minimum bid of $1.00 per share.
Even minute amounts of lead may take a toll on pregnant women, according to a study published by Lynn Goldman, M.D., M.S., M.P.H., Dean of George Washington University's School of Public Health and Health Services in D.C., and colleagues, in the journal Environmental Health Perspectives.
MAP Pharmaceuticals, Inc. today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.
› Verified 3 days ago
| Entity Name | Father Flanagans Boys Home |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295821825 PECOS PAC ID: 9638165400 Enrollment ID: O20040426000622 |
News Archive
A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state in which they are unable to proliferate.
ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it had received a letter dated September 16, 2009, indicating the Company had become non-compliant with the Nasdaq Capital Markets' minimum bid pricing requirement under rule 5550(a)(2) as the Company's closing bid price for the past 30 days had failed to meet the minimum bid of $1.00 per share.
Even minute amounts of lead may take a toll on pregnant women, according to a study published by Lynn Goldman, M.D., M.S., M.P.H., Dean of George Washington University's School of Public Health and Health Services in D.C., and colleagues, in the journal Environmental Health Perspectives.
MAP Pharmaceuticals, Inc. today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Oleg N Militsakh, MD Po Box 10190, Virginia Beach, VA 23450-0190 Ph: (800) 477-5240 | Oleg N Militsakh, MD 8303 Dodge St, Suite # 304, Omaha, NE 68114-4108 Ph: (402) 354-5048 |
News Archive
A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state in which they are unable to proliferate.
ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today it had received a letter dated September 16, 2009, indicating the Company had become non-compliant with the Nasdaq Capital Markets' minimum bid pricing requirement under rule 5550(a)(2) as the Company's closing bid price for the past 30 days had failed to meet the minimum bid of $1.00 per share.
Even minute amounts of lead may take a toll on pregnant women, according to a study published by Lynn Goldman, M.D., M.S., M.P.H., Dean of George Washington University's School of Public Health and Health Services in D.C., and colleagues, in the journal Environmental Health Perspectives.
MAP Pharmaceuticals, Inc. today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.
› Verified 3 days ago
Rahul Mahendra Varman, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 7710 Mercy Rd Ste 3000, Omaha, NE 68124 Phone: 402-932-1999 | |
Tyler Andrew Bliss, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 981225 Nebraska Medical Ctr, Omaha, NE 68198 Phone: 316-208-9184 | |
Debora Goebel, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 720 N 129th St, Omaha, NE 68154 Phone: 402-397-0670 Fax: 402-397-0713 | |
Justin Oltman, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 981225 Nebraska Medical Ctr, Omaha, NE 68198 Phone: 402-559-7005 Fax: 402-559-8940 | |
Anne Kristin Maxwell, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4014 Leavenworth St, Ent Clinic At Laurizten Outpatient Center, Omaha, NE 68105 Phone: 402-559-5208 | |
John W Pflug, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 16929 Frances St, Suite 201 Omaha Ear, Nose & Throat Clinic, Omaha, NE 68130 Phone: 402-758-5330 Fax: 402-758-5339 | |
James V Huerter Jr., MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 17030 Lakeside Hills Plz, Suite 204, Omaha, NE 68130 Phone: 402-758-5600 Fax: 402-758-5169 |